SCHEMBL15528996

SCHEMBL15528996

Cc1ccc(-c2nnc(SCC(=O)Nc3nccs3)[nH]2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.67
▸ CYP1A2 P05177 2/20 0.67
▸ CYP2C9 P11712 2/20 0.67
▸ CYP2C19 P33261 2/20 0.67
▸ HSD17B10 Q99714 2/20 0.67
▸ RAB9A P51151 4/20 0.65
▸ NPC1 O15118 2/20 0.65
▸ MAPT P10636 8/20 0.61
▸ SMN1; SMN2 Q16637 4/20 0.61
▸ TDP1 Q9NUW8 2/20 0.61
▸ MEN1 O00255 6/20 0.61
▸ KMT2A Q03164 6/20 0.61
▸ KDM4E B2RXH2 3/20 0.54
▸ LMNA P02545 1/20 0.54
▸ GLA P06280 1/20 0.54
▸ ALDH1A1 P00352 4/20 0.53
▸ PKM P14618 1/20 0.53
▸ POLB P06746 1/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2404954 0.83 KMT2A (0.65) GAACYP1A2CYP2C9CYP2C19RAB9A
SCHEMBL2404478 0.79 THRB (0.59) GAARAB9ANPC1MAPTSMN1; SMN2
SCHEMBL13831523 0.79 KMT2A (0.65) GAARAB9ANPC1MAPTSMN1; SMN2
SCHEMBL2406242 0.78 L3MBTL1 (0.66) RAB9ANPC1MAPTSMN1; SMN2TDP1
SCHEMBL2405793 0.77 MAPT (0.56) GAAMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL2405792 0.76 THRB (0.61) GAARAB9ANPC1MAPTSMN1; SMN2
SCHEMBL2404394 0.76 THRB (0.56) GAARAB9ANPC1MAPTSMN1; SMN2
SCHEMBL2403534 0.76 CYP1A2 (0.54) GAACYP1A2CYP2C9CYP2C19HSD17B10
SCHEMBL10016449 0.76 MAPT (1.00) CYP1A2CYP2C9CYP2C19RAB9ANPC1
SCHEMBL2403971 0.75 SMN1; SMN2 (0.55) CYP1A2CYP2C9CYP2C19HSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2850068-B1 N-(phenyl)-2-[[3-(phenyl)-1H-1,2,4-triazol-5-yl]thio]-acetamide derivatives and related compounds as G protein coupled receptor 17 (GPCR17) modulators for use in the treatment of neuro-degenerative diseases UNIV DEGLI STUDI MILANO (IT) 2019-05-29 — — EP claimed
US-9879030-B2 GPR17 receptor modulators UNIVERSITA′ DEGLI STUDI DI MILANO (IT) 2018-01-30 — — US claimed
US-20150141410-A1 GPR17 Receptor Modulators UNIVERSITA' DEGLI STUDI DI MILANO (IT) 2015-05-21 — — US claimed
EP-2850068-A1 GPR17 RECEPTOR MODULATORS. Universita' degli Studi di Milano (IT) 2015-03-25 — — EP claimed
WO-2013167177-A1 GPR17 RECEPTOR MODULATORS. UNIVERSITA' DEGLI STUDI DI MILANO (IT) 2013-11-14 — — WO claimed
EP-2850068-B1 N-(phenyl)-2-[[3-(phenyl)-1H-1,2,4-triazol-5-yl]thio]-acetamide derivatives and related compounds as G protein coupled receptor 17 (GPCR17) modulators for use in the treatment of neuro-degenerative diseases UNIV DEGLI STUDI MILANO (IT) 2019-05-29 — — EP disclosed
US-9879030-B2 GPR17 receptor modulators UNIVERSITA′ DEGLI STUDI DI MILANO (IT) 2018-01-30 — — US disclosed
US-20150141410-A1 GPR17 Receptor Modulators UNIVERSITA' DEGLI STUDI DI MILANO (IT) 2015-05-21 — — US disclosed
EP-2850068-A1 GPR17 RECEPTOR MODULATORS. Universita' degli Studi di Milano (IT) 2015-03-25 — — EP disclosed
WO-2013167177-A1 GPR17 RECEPTOR MODULATORS. UNIVERSITA' DEGLI STUDI DI MILANO (IT) 2013-11-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150141410-A1 GPR17 Receptor Modulators GPR65, GPR27, GPR17 GAA 2188/4885CYP1A2 3268/4885CYP2C9 4264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback